A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
OncoResponse, Inc.
OncoResponse, Inc.
Genzada Pharmaceuticals USA, Inc.
ImmVira Pharma Co. Ltd
Merrimack Pharmaceuticals
National Cancer Institute (NCI)